GBT
Income statement / Annual
Last year (2021), Global Blood Therapeutics, Inc.'s total revenue was $194.75 M,
an increase of 57.31% from the previous year.
In 2021, Global Blood Therapeutics, Inc.'s net income was -$303.09 M.
See Global Blood Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$194.75 M |
$123.80 M |
$2.11 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$3.32 M
|
$1.99 M
|
$48,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$191.43 M
|
$121.82 M
|
$2.06 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0.98
|
0.98
|
0.98
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$212.14 M
|
$155.12 M
|
$174.56 M
|
$131.31 M
|
$87.81 M
|
$61.21 M
|
$36.66 M
|
$16.32 M
|
$12.86 M
|
General & Administrative Expenses |
$0.00
|
$0.00
|
$117.09 M
|
$51.44 M
|
$31.44 M
|
$21.92 M
|
$9.67 M
|
$3.86 M
|
$2.31 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$266.99 M
|
$210.85 M
|
$117.09 M
|
$51.44 M
|
$31.44 M
|
$21.92 M
|
$9.67 M
|
$3.86 M
|
$2.31 M
|
Other Expenses |
$0.00
|
$210.85 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$65,000.00
|
$0.00
|
$0.00
|
Operating Expenses |
$479.12 M
|
$365.97 M
|
$291.64 M
|
$182.74 M
|
$119.25 M
|
$83.13 M
|
$46.39 M
|
$20.18 M
|
$15.16 M
|
Cost And Expenses |
$482.44 M
|
$367.96 M
|
$291.69 M
|
$182.74 M
|
$119.25 M
|
$83.13 M
|
$46.39 M
|
$20.51 M
|
$15.66 M
|
Interest Income |
$720,000.00
|
$5.83 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$33,000.00
|
$1,000.00
|
$2,000.00
|
Interest Expense |
$15.47 M
|
$9.81 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Depreciation & Amortization |
$8.62 M
|
$10.82 M
|
$9.93 M
|
$4.61 M
|
$1.66 M
|
$1.24 M
|
$873,000.00
|
$666,000.00
|
$534,000.00
|
EBITDA |
-$278.53 M |
-$226.92 M |
-$256.83 M |
-$169.59 M |
-$115.37 M |
-$81.23 M |
-$45.49 M |
-$20.14 M |
-$17.58 M |
EBITDA Ratio |
-1.43
|
-1.83
|
-121.84
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-1.47
|
-1.96
|
-133.44
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
-$15.47 M
|
-$4.38 M
|
$14.52 M
|
$8.55 M
|
$2.22 M
|
$659,000.00
|
$33,000.00
|
-$296,000.00
|
-$2.45 M
|
Income Before Tax |
-$302.61 M
|
-$247.55 M
|
-$266.77 M
|
-$174.19 M
|
-$117.02 M
|
-$82.47 M
|
-$46.36 M
|
-$20.81 M
|
-$18.12 M
|
Income Before Tax Ratio |
-1.55
|
-2
|
-126.55
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
$477,000.00
|
$5.43 M
|
$14.52 M
|
$8.55 M
|
$2.22 M
|
$659,000.00
|
$33,000.00
|
-$296,000.00
|
-$2.45 M
|
Net Income |
-$303.09 M
|
-$247.55 M
|
-$266.77 M
|
-$174.19 M
|
-$117.02 M
|
-$82.47 M
|
-$46.36 M
|
-$20.81 M
|
-$18.12 M
|
Net Income Ratio |
-1.56
|
-2
|
-126.55
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-4.82 |
-4.04 |
-4.57 |
-3.41 |
-2.76 |
-2.48 |
-3.62 |
-1.51 |
-0.83 |
EPS Diluted |
-4.82 |
-4.04 |
-4.57 |
-3.41 |
-2.76 |
-2.48 |
-3.62 |
-1.51 |
-0.83 |
Weighted Average Shares Out |
$62.93 M
|
$61.33 M
|
$58.32 M
|
$51.15 M
|
$42.32 M
|
$33.21 M
|
$12.81 M
|
$13.76 M
|
$21.80 M
|
Weighted Average Shares Out Diluted |
$62.93 M
|
$61.33 M
|
$58.32 M
|
$51.15 M
|
$42.32 M
|
$33.21 M
|
$12.81 M
|
$13.76 M
|
$21.80 M
|
Link |
|
|
|
|
|
|
|
|
|